Eindhoven’s MedTech startup Xyall secures €7.6 million for global rollout of its automated tissue dissection system

Eindhoven-based MedTech startup Xyall has successfully secured €7.6 million in funding to propel the global expansion of its automated tissue dissection system for molecular pathology. This significant investment, led by Capricorn Partners, highlights a crucial area of innovation within digital health, aiming to enhance precision and efficiency in diagnostic processes. The funding will be instrumental in making Xyall's advanced solutions more accessible to laboratories worldwide. Xyall's technology addresses a critical bottleneck in molecular diagnostics: the manual and often subjective process of selecting tissue for analysis. Their automated solution combines high-resolution imaging, precise image registration, and robotics to accurately identify and dissect specific regions of interest from pathology slides. This digital transformation of a traditionally manual workflow promises to improve the reliability of downstream molecular diagnostic tests, particularly in fields like oncology where personalized treatment is vital. The impact of Xyall's innovation is far-reaching, affecting pathology laboratories, researchers, and ultimately, patients. By automating this labour-intensive step, the system alleviates pressure on laboratory technicians, reduces the risk of errors and cross-contamination, and accelerates turnaround times for diagnostic results. This is especially pertinent given the global shortage of specialized laboratory staff and the increasing demand for faster, more accurate diagnoses to guide therapeutic decisions.